Search - tctmd.com

Displaying 921 - 940 of 1339

Sort: Relevancy | Date

Presentation

Revascularization in Diabetics With Multivessel Disease: Population-Based Evaluation of Outcomes

Presenter: Krishnan Ramanathan

November 16, 2015

News Conference News AHA 2015

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

L.A. McKeown

November 09, 2015

News Conference News AHA 2015

SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients

Todd Neale

November 08, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Daily News

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

Yael L. Maxwell

November 03, 2015

News Daily News

La Puerta se Cierra para las Dietas Bajas en Grasas en lo que al Manejo del Peso a Largo Plazo se refiere

Todd Neale

November 01, 2015

News Daily News

Door Closing on Low-fat Diets for Long-term Weight Management

Todd Neale

November 01, 2015

News Daily News

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Caitlin E. Cox

October 28, 2015

News Industry News

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

October 26, 2015

News Conference News TCT 2015

OCT Feasible for Identifying Factors Related to Stent Thrombosis

October 14, 2015

News Conference News TCT 2015

Thrombus Aspiration Fails to Reduce Microvascular Obstruction in Subacute STEMI

October 13, 2015

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Industry News

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 29, 2015

Presentation Aortovascular 2015

An Office Guide to the Differential Diagnosis of Ulcers

Presenter: Robert Fridman

September 18, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

High Restenosis Rate After CTO Bailout Technique Linked to Suboptimal Flow

September 15, 2015

Advertisement

Revascularization in Diabetics With Multivessel Disease: Population-Based Evaluation of Outcomes

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

La Puerta se Cierra para las Dietas Bajas en Grasas en lo que al Manejo del Peso a Largo Plazo se refiere

Door Closing on Low-fat Diets for Long-term Weight Management

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

OCT Feasible for Identifying Factors Related to Stent Thrombosis

Thrombus Aspiration Fails to Reduce Microvascular Obstruction in Subacute STEMI

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

An Office Guide to the Differential Diagnosis of Ulcers

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

High Restenosis Rate After CTO Bailout Technique Linked to Suboptimal Flow

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content